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Background: 5-Hydroxymethylcytosine (5hmC), converted from 5-methylcytosine (5mC) by ten-eleven translocation
(Tet) enzymes, has recently drawn attention as the “sixth base” of DNA since it is considered an intermediate of the
demethylation pathway. Nonetheless, it remains to be addressed how 5hmC is linked to the development of human
imprinting disorders. In this regard, conventional bisulfite (BS) treatment is unable to differentiate 5hmC from 5mC. It is
thus hypothesized that BS conversion-derived “hypermethylation” at imprinting control regions (ICRs), which may
cause imprinting disorders, would in fact be attributable to excessively increased levels of 5hmC as well as 5mC. To test
this hypothesis, we applied the newly developed oxidative BS (oxBS) treatment to detect 5hmC in blood samples from
Kagami-Ogata syndrome (KOS14) patients caused by an epimutation (hypermethylation) of two differentially
methylated regions (DMRs) functioning as ICRs, namely, IG-DMR and MEG3-DMR.
Findings: oxBS with pyrosequencing revealed that there were few amounts of 5hmC at the hypermethylated IG-DMR
and MEG3-DMR in blood samples from KOS14 patients. oxBS with genome-wide methylation array demonstrated that
global levels of 5hmC were very low with similar distribution patterns in blood samples from KOS14 patients and
normal controls. We also confirmed the presence of large amounts of 5hmC in the brain sample from a normal
control.
Conclusions: 5hmC is not a major component in abnormally hypermethylated ICRs or at a global level, at least in
blood from KOS14 patients. As the brain sample contained large amounts of 5hmC, the neural tissues of KOS14
patients are promising candidates for analysis in elucidating the role of 5hmC in the neurodevelopmental context.
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Background
DNA methylation is a major epigenetic modification of
the mammalian genome that plays a vital role in cellular
processes including gene expression, retrotransposon
silencing, X chromosome inactivation, and genomic im-
printing [1, 2]. Recent studies have highlighted the* Correspondence: kyamazawa@keio.jp
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to enzymatically convert 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC) through Fe(II)/α-keto-
glutarate-dependent hydroxylation [3–5]. Additional
oxidative steps to generate 5-formylcytosine (5fC) and
5-carboxylcytosine (5caC), and the following base ex-
cision repair mechanism would lead to removal of the
methylated base and its replacement with an unmethy-
lated cytosine (C) in a DNA replication-independent man-
ner [5–9]. Alternatively, 5hmC converted from 5mC by
Tet enzymes can be diluted through subsequent rounds of
DNA replication and cell division due to the low enzym-
atic activity of Dnmt1 on the hemi-hydroxymethylatedrticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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vides a direct mechanistic pathway for both active and
passive DNA demethylation, suggesting an important role
of 5hmC in diverse biological processes through the regu-
lation of DNA methylation states.
Methylation levels of cytosines have usually been
evaluated using a reaction with sodium bisulfite (BS)
followed by PCR amplification [11]. BS treatment
yields deamination of C to uracil that is read as thy-
mine (T) in subsequent assays. In contrast, 5mC is
resistant to deamination by BS and is thus read as C.
In this regard, it is noteworthy that this BS treatment
does not distinguish between 5mC and 5hmC because
5hmC is also resistant to deamination [12, 13], raising
the possibility that BS-based analyses so far could po-
tentially overestimate 5mC levels in a given sample
due to the presence of 5hmC.
Thus far, our laboratory has extensively investigated
the features of human imprinting disorders mainly at-
tributable to abnormal methylation, especially Kagami-
Ogata syndrome (KOS14), which is characterized by a
unique array of clinical features including facial abnor-
malities, a small bell-shaped thorax with coat-hanger
appearance of the ribs, abdominal wall defects, placen-
tomegaly, and polyhydramnios [14–17]. One of the
causative molecular mechanisms of KOS14 is aberrant
hypermethylation of the paternally methylated differen-
tially methylated regions (DMRs) functioning as im-
printing control regions (ICRs), i.e., the germline-
derived IG-DMR and postfertilization-derived MEG3-
DMR, which perturbs the expression of clustered
imprinted genes on 14q32.2. In particular, the markedly
elevated RTL1 expression primarily causes the KOS14
phenotype [14, 15]. However, to date, there have been
no reports that investigate the functional role of hydro-
xymethylation in human imprinting disorders caused
by abnormal hypermethylation.
To clarify this issue, we utilized the newly devel-
oped modified bisulfite technique in conjunction with
the high-throughput Infinium HumanMethylation450
BeadChip, as well as pyrosequencing and cloning-
based sequencing, to detect the 5hmC level in KOS14
blood samples caused by imprinting defects due to
hypermethylation of the IG-DMR and MEG3-DMR.
In particular, we tested the hypothesis that conven-
tional BS conversion-derived “hypermethylation” could
in fact be attributable to excessively increased levels
of 5hmC as well as 5mC. In this context, based on
the notion that 5hmC functions as an intermediate in
an active DNA demethylation pathway by Tet-driven
oxidative steps, 5hmC could be generated at the ICRs,
perhaps as a consequence of a self-correcting mech-
anism that allows abnormally hypermethylated alleles
to be demethylated.Methods summary
Detailed methods are available in Additional file 1.
Samples
We analyzed blood genomic DNA from three patients
molecularly diagnosed as KOS14 with an epimutation
(hypermethylation) involving the IG-DMR and MEG3-
DMR, pooled blood genomic DNA from ten normal con-
trol subjects, and purchased human brain genomic DNA.
All procedures followed were in accordance with the eth-
ical approval granted by the institutional review boards at
the National Center for Child Health and Development
(project 518), and written informed consent was obtained
from all participants.
BS/oxidative BS conversion
We applied oxidative BS (oxBS) treatment whereby se-
lective chemical oxidation converts 5hmC into 5fC, and
subsequent BS treatment converts 5fC and C into uracil
(later T). Consequently, the “methylation” level derived
by the BS treatment is the combined levels of 5mC and
5hmC, while the oxBS treatment gives the level of 5mC
alone. The 5hmC value is thus derived by subtracting
the oxBS level from the BS level [18].
oxBS pyrosequencing, cloning-based sequencing, and
methylation array analysis
First, oxBS pyrosequencing was carried out to analyze
methylation and hydroxymethylation status at the IG-
DMR and MEG3-DMR with BS- and oxBS-treated sam-
ples. Because the 450K BeadChip probes described
below did not cover the IG-DMR region, cloning-based
sequencing for the IG-DMR was also performed.
Next, the BS- or oxBS-treated samples were applied
to an Infinium HumanMethylation450 BeadChip Kit
(Illumina) and processed following the manufacturer’s
recommendations (BS/oxBS-array). The methylation
level at each probe was represented by β values ranging
from 0 (completely unmethylated) to 1 (completely
methylated). 5hmC levels were thus calculated by sub-
traction (Δβ) of the β value of oxBS-treated samples,
representing 5mC only, from the β value of BS-treated
samples, representing 5mC and 5hmC, at each probe
site.
Results
Methylation/hydroxymethylation at the IG-DMR and MEG3-
DMR
The pyrosequencing results revealed that, as expected,
the “methylation” values derived by BS reaction at the
IG-DMR and MEG3-DMR in KOS14 patients were con-
siderably high compared to those in the blood/brain
samples of the normal control (Fig. 1a and Additional
file 2: Figure S1). The values derived by oxBS reaction at
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KOS14 patients, whereas those in the control blood/
brain were normal. The result of subtraction of the oxBS
values from the BS values, which corresponds to the
5hmC level at each CpG, was nearly zero in all KOS14
patients, as well as the control blood/brain samples.
The results of BS/oxBS cloning-based sequencing for
the IG-DMR were consistent with those of pyrosequenc-
ing, i.e., there were no apparent differences between the
dot patterns of BS and oxBS treatment in blood samples
from KOS14 and the normal control, indicating that
5hmC rarely existed at the IG-DMR in blood samples
(Fig. 1b). Of note, some CpG sites in the brain sample
from the control showed disparity in methylation levels
between BS and oxBS treatment, suggesting that some
5hmC distributed in a CpG site-specific manner only in
the brain, though statistical comparisons were generally
inapplicable in this cloning-based assay. It is also note-
worthy that heterozygous SNP (rs10133627) allowed the
discrimination of the parental origin of each clone in
blood samples obtained from patient 1 and the normal
control; however, parental origin-specific distribution of
5hmC was not observed in these samples.
BS/oxBS-array
Using a detection P value threshold of 0.01 to filter
probes, we found that the technical replicates for both
BS and oxBS conversion showed a strong correlation of
r = 0.97–0.99 (Additional file 3: Figure S2), indicating aFig. 1 Methylation/hydroxymethylation analysis by BS and oxBS treatmen
pyrosequencing with BS or oxBS conversion for three KOS14 blood samp
brain sample. Solid lines denote values with BS, whereas dotted lines denote th
sequencing with BS or oxBS conversion for one KOS14 blood sample (Pt1), on
open circles indicate (methylated + hydroxymethylated) and unmethylated cy
indicate methylated and (hydroxymethylated + unmethylated) cytosines at th
also denoted. Note this control blood sample was derived from a single persohigh degree of reproducibility. Thus, we used the aver-
age of these replicates as the final measurement of 5mC
and 5hmC. Hierarchical clustering of arrays on β value
showed a clear separation between blood and brain sam-
ples (Additional file 4: Figure S3). Note there were
distinct differences between clusterings of BS and oxBS
conversion samples in brain tissue, implying a consider-
able amount of 5hmC in the brain.
Density plots of normalized β values for three KOS14
blood samples, one control pooled blood sample, and
one adult brain sample represented a bimodal distribu-
tion for both BS and oxBS conversion samples (Fig. 2a).
It is also noteworthy that the methylated peaks (larger β
value peaks) were left-skewed only in the oxBS brain
sample, corresponding to lower global methylation/
higher hydroxymethylation levels in the brain. No differ-
ence between the three KOS14 blood samples and the
control pooled blood sample was observed.
Distribution of the Δβ score (as a reflection of the
5hmC level at each particular probe position) of each
sample is shown in Fig. 2b. The median level of Δβ in
the brain sample was higher than those in blood samples
from KOS14 patients and pooled controls, which were
very close to zero. Table 1 shows the number of probes
with Δβ ≥ 0.1. While 28.3 % of the probes showed
Δβ ≥ 0.1 in the control brain sample, only 1–3 % of
the probes with Δβ ≥ 0.1 were observed in blood sam-
ples from KOS14 patients, as well as the normal con-
trols. The number of probes with Δβ ≥ 0.1 was similart at the IG-DMR. a Methylation values (%methylation) determined by
les (Pt1–Pt3), one control pooled blood sample, and one control adult
ose with oxBS. b Methylation profiles determined by cloning-based
e control blood, and one control adult brain sample. For BS, filled and
tosines at the CpG sites, respectively, while for oxBS, filled and open circles
e CpG sites, respectively. The typing data of A/G SNP (rs10133627) are
n, rather than a pooled blood sample
Fig. 2 Representative data of BS/oxBS-array. a Density plots of normalized beta values with BS and oxBS conversion for three KOS14 blood samples
(Pt1–Pt3), one control pooled blood sample, and one control adult brain sample. Beta values show a bimodal distribution for both BS and oxBS conversion
samples. Of note, a left-skewed methylated peak is observed in the oxBS brain sample. b Box and whisker plots of Δβ score (corresponding to 5hmC value)
for each sample. c Distribution of probes with Δβ≥ 0.1 according to genomic features for each sample
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normal controls. Notably, we investigated six specific
individual CpG sites where high levels of 5hmC were
previously validated in brain samples by Stewart et al.
[19], and confirmed substantial amounts of 5hmC at
the same sites only in the brain sample in our assay
as well (Additional file 5: Table S1).
We next investigated the distribution of probes with
Δβ ≥ 0.1, i.e., hydroxymethylated probes according to
genomic features (Fig. 2c). Although the overall propor-
tion of hydroxymethylated probes was much higher in
the brain sample than in the blood samples, distribution
patterns of hydroxymethylated probes in genomic
regions were similar among all samples analyzed. Over-
all, the proportion of hydroxymethylated probes showed
a decrease at the CpG islands, and at TSS 200 and first
exon regions in all samples, consistent with previous re-
ports that demonstrated an inverse correlation between
5hmC and CpG density at the promoter [18–20].Table 1 Number of probes with Δβ≥ 0.1
Δβ≥ 0.3 0.3 > Δβ ≥ 0.2
Pt1 (blood) 7 197
Pt2 (blood) 8 296
Pt3 (blood) 3 68
Control (blood) 2 147
Control (brain) 8215 30,652Afterwards, we looked into the average β values of 32
probes encompassing the MEG3-DMR (Additional file 6:
Figure S4A). The average β values of both BS- and
oxBS-treated samples were higher in patients with
KOS14 than in the normal control blood/brain. How-
ever, Δβ values were remarkably subtle, indicating that
only small amounts of 5hmC existed at the MEG3-DMR
in blood samples from three patients with KOS14 as well
as the control pool, similarly at the IG-DMR and other
genomic loci.
Finally, we inquired into the data of other DMRs outside
chromosome 14 (Additional file 6: Figure S4B–H). Over-
all, there was no difference between the average β values
of BS-treated blood samples from patients with KOS14
and those from the normal control, indicating that mul-
tiple methylation defects were not observed in these three
patients. Moreover, Δβ values were remarkably subtle in
all blood samples analyzed, demonstrating that small
amounts of 5hmC existed at other DMRs as well as at the0.2 > Δβ≥ 0.1 Total number of probes with Δβ ≥ 0.1
6309 6513 (1.5 %)
8819 9123 (2.1 %)
3416 3487 (0.81 %)
7026 7175 (1.7 %)
83,294 122,161 (28.3 %)
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probes had relatively high Δβ values, especially at the
PEG10-DMR, MEST-DMR, and GNAS exon A/B-DMR,
suggesting that substantial amounts of 5hmC were in-
cluded at these DMRs in the brain.
Discussion
In this study, we analyzed the 5hmC level and distribu-
tion pattern using the newly developed oxBS treatment
combined with pyrosequencing, cloning-based sequen-
cing, and the 450K methylation array in peripheral blood
taken from three patients with KOS14 and normal con-
trols, and in the brain sample from the normal control.
This is the first study to investigate hydroxymethylation
in human imprinting disorders caused by abnormal
hypermethylation at ICRs and provides several notable
findings.
First, our study found few amounts of 5hmC at the
IG-DMR and MEG3-DMR as well as at other DMRs or
a genome-wide level in blood samples from KOS14 pa-
tients. Although we hypothesized that conventional BS
conversion-derived “hypermethylation” would be in fact
attributable to excessively increased levels of 5hmC in
addition to 5mC, our data did not support this hypoth-
esis. Taking into account that 5hmC has been proposed
to be an intermediate in an active DNA demethylation
pathway by Tet-mediated oxidative steps, 5hmC was as-
sumed to be yielded perhaps as a consequence of a self-
correcting mechanism, which enables abnormally hyper-
methylated alleles to be demethylated. However, this is
not applicable at least to the blood samples, which con-
tain a very small amount of 5hmC.
Second, BS/oxBS-array methods are powerful tools
for (hydroxy)methylation profiling, suitable for high-
throughput sample processing and genome-wide 5mC/
5hmC mapping. In this context, Stewart et al. devel-
oped and utilized the oxBS-array to measure 5hmC in
normal human blood and brain samples [19]. They vali-
dated that six individual CpG sites contained a substan-
tial amount of hydroxymethylation in the brain. We
confirmed abundant levels of 5hmC at the same sites
only in the brain, suggesting that our assay worked
properly. This is supported by the findings of a high de-
gree of reproducibility in technical replicates and a
clear separation between blood and brain samples in
hierarchical clustering on β values.
Third, 5hmC in neural samples derived from KOS14
patients is a promising candidate for future analysis. In
this regard, the highest levels of 5hmC are observed in
neural tissues [13, 21]. Our BS/oxBS-array data have
supported this at some DMRs, as well as at a genome-
wide level. In addition, neurodevelopmental problems
are one of the major symptoms of KOS14 [17]. Further-
more, several studies have recently shown that thedysregulation of 5hmC could be involved in neuro-
logical disorders such as Rett syndrome, fragile X syn-
drome, Huntington’s disease, and Alzheimer’s disease
[22–25]. Although it seems to be difficult to obtain
neural samples from KOS14 patients, induced pluripo-
tent stem (iPS) cell-based disease modeling derived
from KOS14 patients and its neural differentiation can
be one of the most promising approaches.
In summary, this study is the first to demonstrate that,
at least in the blood, 5hmC is not a major component of
the abnormally hypermethylated ICR that causes human
imprinting disorders. In addition, genome-wide analysis
revealed that global levels of 5hmC were very subtle with
similar distribution patterns in blood samples taken
from KOS14 patients and normal controls. Given that a
large amount of 5hmC exists in the brain, further studies
of neural tissues are required to better understand the
biological role of 5hmC in the neurodevelopmental
context.
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